Low-dose rituximab is effective in pemphigus
- 3 October 2011
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 166 (2) , 405-412
Abstract
Background Rituximab, an anti‐CD20 antibody, was shown in open series studies to be effective in treating pemphigus at a dose of 4 × 375 mg m−2 as approved for B‐cell malignancies. Objectives We investigated whether a lower dose of rituximab is also effective for pemphigus. Methods Patients with pemphigus were treated with a single course of two infusions of rituximab (500 mg each) at an interval of 2 weeks. Clinical consensus late end points, B‐cell number, desmoglein 1 and desmoglein 3 indices were monitored. Results We enrolled 15 patients in the study: three with pemphigus foliaceus (PF) and 12 with pemphigus vulgaris (PV). The follow‐up was 32–152 weeks (median 94). All 15 patients responded to therapy. Eight patients achieved complete remission in a median period of 51 weeks (four on minimal therapy, four off therapy). Seven patients achieved partial remission in a median period of 34·5 weeks (five on minimal therapy, two off therapy). Relapses (40%) were seen between 53 and 103 weeks (median 97) after start of therapy. B‐cell numbers dropped to < 1% after first infusion, and remained undetectable in patients with sustained remission. The antidesmoglein 1 index correlated well with the clinical severity in PF, but this was less obvious in PV. Conclusions A low dose of rituximab is an effective and safe treatment for pemphigus. Relapses may occur, mostly at the end of the second year. Cost–effectiveness studies with a long follow‐up are required to determine the proper dosage of this expensive drug in pemphigus.Keywords
This publication has 34 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009Annals of the Rheumatic Diseases, 2010
- Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysisArthritis & Rheumatism, 2007
- Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2007
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusNew England Journal of Medicine, 2007
- Treatment of Severe Pemphigus With RituximabArchives of Dermatology, 2007
- Off-label uses of rituximab in dermatologyDermatologic Therapy, 2007
- Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus?Dermatology, 2007
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinNew England Journal of Medicine, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLLAmerican Journal of Hematology, 2001